| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 441 | 2021 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 110 | 2023 |
| LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for unresectable … DW Miles, J Gligorov, F André, D Cameron, A Schneeweiss, CH Barrios, ... Annals of Oncology 31, S1147-S1148, 2020 | 110 | 2020 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 59 | 2023 |
| IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Ann Oncol 32 (8), 994-1004, 2021 | 49 | 2021 |
| Aplicação dos métodos de identificação humana post mortem no IML Estácio de Lima no período de janeiro de 2011 a dezembro de 2015 L Andrade Perspec Medicina Legal Per Med 4 (2), 3, 2017 | 12 | 2017 |
| Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and … F Maluf, A Soares, G Avanço, AL Hada, APG Cardoso, A Carneiro, ... International braz j urol 47, 359-373, 2021 | 6 | 2021 |
| Age and treatment of lung cancer in Brazil JP Pereira, SJ Martins, LM Andrade Proc Am Soc Clin Oncol 19, 548a, 2000 | 5 | 2000 |
| Avaliação de populações locais de abóbora menina (Cucurbita maxima Duch. ex Lam) A Marreiros, JB Sousa, L Andrade, MF Quedas, J Leitão, I Veiga, ... V Congresso Ibérico de Ciências Hortícolas, IV Congresso Iberoamericano de …, 2005 | 2 | 2005 |
| Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for … V Gennusa, C Saieva, RM Lee-Ying, PV Nuzzo, GP Spinelli, E Zanardi, ... Journal of Clinical Oncology 41 (6_suppl), 166-166, 2023 | 1 | 2023 |
| Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy … PV Nuzzo, F Pederzoli, C Saieva, E Zanardi, G Fotia, A Malgeri, ... Journal of Translational Medicine 21 (1), 75, 2023 | 1 | 2023 |
| Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial N Shore, K Fizazi, T Tammela, L Murilo, MP Salas, P Ouellette, S Lago, ... Genitourinary Cancers Symposium, 2021 | 1 | 2021 |
| Application of post mortem human identification methods, in the LMI Estácio de Lima, in the period of January 2011 to December 2015 APC Carneiro, LM ANDRADE, FJO FRAGA, ML Duarte Rev. Perspectivas, 2017 | 1 | 2017 |
| Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study ND Shore, K Fizazi, TLJ Tammela, M Luz, MP Salas, P Ouellette Jr, ... European Journal of Cancer 195, 113342, 2023 | | 2023 |
| Analysis of the Effect of Crossover From Placebo (PBO) to Darolutamide (DARO) on Overall Survival (OS) Benefit in the ARAMIS Trial N Oliveira, N Shore, K Fizazi, T Tammela, M Luz, MP Salas, P Ouellette Jr, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 17, 39-40, 2021 | | 2021 |
| Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS trial K Schlack, N Shore, K Fizazi, T Tammela, M Luz, MP Salas, P Ouellette Jr, ... ONCOLOGY RESEARCH AND TREATMENT 44, 263-263, 2021 | | 2021 |
| • Primary results from IMpasion131, a double blind placebo-controlled randomized phase III trial of first line paclitaxel (PAC) +- Atezolizumab (atezo) for unresectable … JOS D.W. Miles1, J. Gligorov2, F. André3, D. Cameron4, A. Schneeweiss5, C.H ... Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc …, 2020 | | 2020 |
| Tumor de Células Epitelioides Perivasculares(PEComa) Maligno do Retroperitoneo DB Livia Andrade, Pamela Almeida, Mayanna Lopes, Stella Dourado, Tamara Santana Rev. Saude HSI.2014 ; 1 Mar : 44-47, 2014 | | 2014 |
| P2-285: Metronomic chemotherapy in pre-treated patients with advanced or metastatic lung cancer: a preliminary report from a single-centre compassionate use programme SJ Martins, CA Yamamoto, JA Sousa, IB Vasconcelos, L Andrade, A Motta Journal of Thoracic Oncology 2 (8), S685, 2007 | | 2007 |
| [Evaluation of local populations of pumpkins [Portugal]] A Marreiros, JB de Sousa, L Andrade, F Quedas, J Leitão, I Veiga, ... | | 2005 |
